成都医元智创科技有限公司是一家从事数字化医疗服务、3D个性化医疗器械研发及生产的高科技企 业。公司拥有国内少数能实现多模态数字化重建的数字医疗团队，长期致力于医疗3D领域高新技术的 研究及应用，拥有自主知识产权的医疗3D打印开放式服务系统，为临床医生及患者提供全球领先的个 性化定制医疗3D解决方案。已取得专利30余项，制定团体标准1项。 证券之星消息，根据天眼查APP于1月21日公布的信息整理，成都医元智创科技有限公司Pre-A轮融资， 融资额未披露，参与投资的机构包括策源资本。 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Insights - Novo Nordisk announced a comprehensive upgrade of its "Health Ecosystem Alliance" at the 8th China International Import Expo, transitioning from a singular focus on digital healthcare to a collaborative cross-industry approach [1] Group 1: Digital Health Ecosystem - The "Health Ecosystem Alliance" aims to establish an "online + offline" intelligent chronic disease management network, integrating data from doctors, pharmaceutical companies, and medical devices to create a sustainable closed loop [2] - The alliance has partnered with major health platforms like Alibaba Health, JD Health, and Tencent Health to build a digital chronic disease management ecosystem, emphasizing early screening, diagnosis, and treatment [2] Group 2: Device Connectivity and Data Integration - Novo Nordisk will collaborate with Weitai Medical and Yuyue Medical to integrate insulin pen and dynamic blood glucose meter data, enabling visualized management of blood glucose and medication for patients [3] - The partnership with Huawei Health will incorporate exercise and heart rate data into the "Novo Care" platform, creating a comprehensive health profile for users [3] Group 3: Product Launches - The launch of the Harmony version of the "Novo Care" app, compatible with Huawei devices, and the weight management version focuses on providing customized health management solutions for diabetes, rare diseases, and obesity [4] - The new app versions aim to enhance user experience by offering features like disease education, smart medication guidance, and a "pharmacy map" [4] Group 4: Patient-Centric Approach - Novo Nordisk's senior vice president emphasized that digital innovation is reshaping chronic disease management, aiming to create a future-oriented health service model through collaboration with leading digital ecosystem partners in China [5] - The company's goal extends beyond drug innovation to enhancing public health literacy and supporting the "Healthy China" strategy through digital services [5]